A Single-Center, Clinical Study to Evaluate the Safety of a New Personal Lubricant in Healthy Female Subjects

Sponsor
Church & Dwight Company, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT02737852
Collaborator
(none)
32
1
1
2
16

Study Details

Study Description

Brief Summary

To evaluate the safety of a new personal lubricant when used at least four times weekly for two weeks (including at least twice weekly during sexual intercourse for subjects with monogamous male partners), in a population consisting of healthy females.

Condition or Disease Intervention/Treatment Phase
  • Device: Trojan "Chameleon" Personal Lubricant
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
32 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Masking Description:
The new personal lubricant was used by all participants
Primary Purpose:
Other
Study Start Date :
Mar 1, 2016
Actual Primary Completion Date :
May 1, 2016
Actual Study Completion Date :
May 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Healthy subject

Healthy subject exposed to Trojan "Chameleon" Personal Lubricant at least four times weekly for two weeks

Device: Trojan "Chameleon" Personal Lubricant
silicone base with sensate

Outcome Measures

Primary Outcome Measures

  1. Number of Subjects With Observed Local Erythema Based on the 5 Point Scoring Scale [2 weeks]

    Number of subjects with observed local erythema by obstetrician/gynecologist examination as graded on 5 point clinical scale: 0 = normal appearance no irritation, 0.5 = slight, irregular erythema, 1 = mild erythema, 2 = moderate erythema 3 = severe erythema

  2. Number of Subjects With Observed Edema Based on the 5 Point Scoring Scale [2 weeks]

    Number of subjects with observed local edema by obstetrician/gynecologist examination as graded on 5 point clinical scale: 0 = normal appearance no edema, 0.5 = slight edema, 1 = mild edema, 2 = moderate edema 3 = severe edema

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • no participation in a similar study 2-weeks prior

  • may be post-menopausal or have had a hysterectomy

  • if sexually active, and of child bearing potential, subjects using adequate non-barrier method of birth control

  • free from any vaginal disorders

  • sexually active and monogamous, heterosexual relationship, and whose male partner is willing and able to give informed consent and agrees to engage in sexual intercourse at least twice each week during the two-week study or is not sexually active

  • personal lubricant user and agrees to replace her usual personal lubricant with the investigational product

  • can start regardless of where they are in their cycles

  • agrees to use the provided investigational product at least four times weekly over the two week study period

  • exhibits no clinically significant evidence of vulvar or vaginal irritation, as determined by a study doctor, and no reports of sensory irritation at the baseline exam

  • willing to refrain from introducing any new vaginal products, or using vaginal medications or local contraceptives during study

  • agrees to refrain from douching or using any medications, powder, lotions or personal care products in the vulvar or perianal area

  • willing to use a urine pregnancy test provided to them at baseline and on third visit

  • standard medical history form on file

  • signed informed consent

  • completed HIPAA

  • dependable and able to follow directions as outlined

  • receives a score of 0 or 0.5 for erythema and edema: and 0 for sensorial irritation (burning, stinging, itching and dryness) during the first examination.

Exclusion Criteria:
  • pregnant, nursing or planning a pregnancy

  • currently using or has used within two weeks prior to the study initiation, any systemic or topical corticosteroids, vasoconstrictors, antibiotics, anti-inflammatories or antihistamines

  • known allergies to vaginal or any cosmetic products

  • reports history of recurrent bladder, vaginal infections or incontinence

  • exhibits or reports gynecologic abnormalities or has had vaginitis within 60 days prior to study initiation

  • uses a vaginal ring, diaphram or cervical/vault caps, condoms, or condoms with spermicide as a means of contraception

  • participated in a study involving the vaginal area or in an investigational systemic drug study within two weeks of study initiation

  • receives a score higher than 0/5 for erythema, edema or >0 for burning, stinging, or itching, during first examination or shows any other sign of mucosal irregularities

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinical Research Laboratories, LLC Piscataway New Jersey United States 08854

Sponsors and Collaborators

  • Church & Dwight Company, Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Church & Dwight Company, Inc.
ClinicalTrials.gov Identifier:
NCT02737852
Other Study ID Numbers:
  • ST-7609
First Posted:
Apr 14, 2016
Last Update Posted:
Sep 1, 2017
Last Verified:
Aug 1, 2017
Additional relevant MeSH terms:

Study Results

Participant Flow

Recruitment Details
Pre-assignment Detail
Arm/Group Title Healthy Subject
Arm/Group Description Healthy subject exposed to Trojan "Chameleon" Personal Lubricant at least four times weekly for two weeks Trojan "Chameleon" Personal Lubricant: silicone base with sensate
Period Title: Overall Study
STARTED 32
COMPLETED 30
NOT COMPLETED 2

Baseline Characteristics

Arm/Group Title Healthy Subject
Arm/Group Description Healthy subject exposed to Trojan "Chameleon" Personal Lubricant at least four times weekly for two weeks Trojan "Chameleon" Personal Lubricant: silicone base with sensate
Overall Participants 30
Age, Customized (Count of Participants)
Age 19-59
30
100%
Sex: Female, Male (Count of Participants)
Female
30
100%
Male
0
0%
Race and Ethnicity Not Collected (Count of Participants)

Outcome Measures

1. Primary Outcome
Title Number of Subjects With Observed Local Erythema Based on the 5 Point Scoring Scale
Description Number of subjects with observed local erythema by obstetrician/gynecologist examination as graded on 5 point clinical scale: 0 = normal appearance no irritation, 0.5 = slight, irregular erythema, 1 = mild erythema, 2 = moderate erythema 3 = severe erythema
Time Frame 2 weeks

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group Title Healthy Subject
Arm/Group Description Healthy subject exposed to Trojan "Chameleon" Personal Lubricant at least four times weekly for two weeks Trojan "Chameleon" Personal Lubricant: silicone base with sensate
Measure Participants 30
Count of Participants [Participants]
0
0%
2. Primary Outcome
Title Number of Subjects With Observed Edema Based on the 5 Point Scoring Scale
Description Number of subjects with observed local edema by obstetrician/gynecologist examination as graded on 5 point clinical scale: 0 = normal appearance no edema, 0.5 = slight edema, 1 = mild edema, 2 = moderate edema 3 = severe edema
Time Frame 2 weeks

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group Title Healthy Subject
Arm/Group Description Healthy subject exposed to Trojan "Chameleon" Personal Lubricant at least four times weekly for two weeks Trojan "Chameleon" Personal Lubricant: silicone base with sensate
Measure Participants 30
Count of Participants [Participants]
0
0%

Adverse Events

Time Frame
Adverse Event Reporting Description
Arm/Group Title Healthy Subject
Arm/Group Description Healthy subject exposed to Trojan "Chameleon" Personal Lubricant at least four times weekly for two weeks Trojan "Chameleon" Personal Lubricant: silicone base with sensate
All Cause Mortality
Healthy Subject
Affected / at Risk (%) # Events
Total / (NaN)
Serious Adverse Events
Healthy Subject
Affected / at Risk (%) # Events
Total 0/30 (0%)
Other (Not Including Serious) Adverse Events
Healthy Subject
Affected / at Risk (%) # Events
Total 0/30 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

Master service agreement and confidentiality agreement in place

Results Point of Contact

Name/Title Annahita Ghassemi
Organization Church & Dwight Co., Inc
Phone 6098061200
Email annhita.ghassemi@churchdwight.com
Responsible Party:
Church & Dwight Company, Inc.
ClinicalTrials.gov Identifier:
NCT02737852
Other Study ID Numbers:
  • ST-7609
First Posted:
Apr 14, 2016
Last Update Posted:
Sep 1, 2017
Last Verified:
Aug 1, 2017